The Efficacy of Different Inflammatory Markers for the Prognosis of Patients with Malignant Tumors

Zheng, Kaiwen; Liu, Xiangliang; Ji, Wei; Lu, Jin Song; Cui, Jiuwei; Li, Wei

doi:10.2147/jir.s334941

Cited by 14 publications

(14 citation statements)

References 61 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zheng et al. analyzed different indicators of 2415 patients with malignant tumors and reported that a high SII was a predictor of a worse prognosis of patients with malignancies ( 15 ). In a study of PTC patients, Muzza et al.…”

Section: Discussionmentioning

confidence: 99%

“…The absolute value of platelets × absolute value of neutrophils/absolute value of lymphocytes is a comprehensive index of platelets, neutrophils, and lymphocytes, and it can reflect immune function to a certain extent. Zheng et al analyzed different indicators of 2415 patients with malignant tumors and reported that a high SII was a predictor of a worse prognosis of patients with malignancies (15). In a study of PTC patients, Muzza et al reported the elevated expression of inflammatory molecules (16), while Zhang et al studied 406 patients and showed that SII was a marker for predicting central lymph node metastasis (17).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Blood immune indexes can predict lateral lymph node metastasis of thyroid papillary carcinoma

et al. 2022

View full text Add to dashboard Cite

ObjectiveTo explore the clinical significance of blood immune indexes in predicting lateral lymph node metastasis (LLNM) of thyroid papillary carcinoma (PTC).MethodsThe pathological data and preoperative blood samples of 713 patients that underwent thyroid surgery at affiliated Hangzhou First People’s Hospital Zhejiang University School of Medicine from January 2013 to June 2021 were collected as the model group. The pathological data and preoperative blood samples of 177 patients that underwent thyroid surgery in the same hospital from July 2021 to October 2021 were collected as the external validation group. Univariate and multivariate logistic regression analyses were used to determine the independent risk factors of LLNM in PTC patients. A predictive model for assessing LLNM in PTC patients was established and externally validated using the external data.ResultsAccording to univariate and multivariate logistic regression analyses, tumor diameter (P < 0.001, odds ratios (OR): 1.205, 95% confidence interval (CI): 1.162–1.249) and the preoperative systemic immune-inflammation index (SII) (P = 0.032, OR: 1.001, 95% CI: 1.000–1.002) were independent risk factors for distinguishing LLNM in PTC patients. When the Youden index was the highest, the area under the curve (AUC) was 0.860 (P < 0.001, 95% CI: 0.821–0.898). The externally validated AUC was 0.827 (P < 0.001, 95% CI: 0.724–0.929), the specificity was 86.4%, and the sensitivity was 69.6%. The calibration curve and the decision curve indicated that the model had good diagnostic value.ConclusionBlood immune indexes can reflect the occurrence of LLNM and the biological behavior of PTC. The predictive model established in combination with SII and tumor diameter can effectively predict the occurrence of LLNM in PTC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Blood immune indexes can predict lateral lymph node metastasis of thyroid papillary carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Combined indexes have been determined to define the condition of systemic inflammation as the platelet-lymphocytes ratio (PLR), monocytelymphocyte ratio (MLR), neutrophil-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) (7). These lymphocyte indexes have been correlated to prognosis in many solid tumors and are considered applicable in clinical practice as reliable independent prognostic markers (8)(9)(10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment

Gianni

Palleschi²,

Schepisi³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Adaptive and innate immune cells play a crucial role as regulators of cancer development.Inflammatory cells in blood flow seem to be involved in pro-tumor activities and contribute to breast cancer progression. Circulating lymphocyte ratios such as the platelet-lymphocytes ratio (PLR), the monocyte-lymphocyte ratio (MLR) and the neutrophil-lymphocyte ratio (NLR) are new reproducible, routinely feasible and cheap biomarkers of immune response. These indexes have been correlated to prognosis in many solid tumors and there is growing evidence on their clinical applicability as independent prognostic markers also for breast cancer.In this review we give an overview of the possible value of lymphocytic indexes in advanced breast cancer prognosis and prediction of outcome. Furthermore, targeting the immune system appear to be a promising therapeutic strategy for breast cancer, especially macrophage-targeted therapies. Herein we present an overview of the ongoing clinical trials testing systemic inflammatory cells as therapeutic targets in breast cancer.

show abstract

“…It has also been confirmed that some demographic characteristics are of great value in predicting the survival time of NSCLC; these include sex, age (Wang et al, 2019), chronic obstructive pulmonary disease (COPD) status (Loganathan et al, 2006;Ytterstad et al, 2016), and smoking status (de Groot and Munden, 2012). Various inflammatory factors, such as the Glasgow prognostic score (GPS) (Sandfeld-Paulsen et al, 2019;Imai et al, 2021), systemic immune-inflammation index (SII) (Tong et al, 2017;Zheng et al, 2021), NLR (Diem et al, 2017;Bongiovanni et al, 2021), and Aarhus composite biomarker score (ACBS) (Sandfeld-Paulsen et al, 2019), have been validated as prognostic markers in lung cancer.…”

Section: Introductionmentioning

confidence: 99%

A Low Advanced Lung Cancer Inflammation Index Predicts a Poor Prognosis in Patients With Metastatic Non–Small Cell Lung Cancer

Lü

Kai

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Introduction: Inflammation plays a crucial role in cancers, and the advanced lung cancer inflammation index (ALI) is considered to be a potential factor reflecting systemic inflammation.Objectives: This work aimed to explore the prognostic value of the ALI in metastatic non–small cell lung cancer (NSCLC) and classify patients according to risk and prognosis.Methods: We screened 318 patients who were diagnosed with stage IV NSCLC in Hubei Cancer Hospital from July 2012 to December 2013. The formula for ALI is body mass index (BMI, kg/m2) × serum albumin (Alb, g/dl)/neutrophil–lymphocyte ratio (NLR). Categorical variables were analyzed by the chi-square test or Fisher’s exact test. The overall survival (OS) rates were analyzed by the Kaplan–Meier method and plotted with the R language. A multivariate Cox proportional hazard model was used to analyze the relationship between ALI and OS.Results: According to the optimal cut-off value determined by X-tile software, patients were divided into two groups (the ALI <32.6 and ALI ≥32.6 groups), and the median OS times were 19.23 and 39.97 months, respectively (p < 0.01). A multivariable Cox regression model confirmed that ALI and chemotherapy were independent prognostic factors for OS in patients with NSCLC. OS in the high ALI group was better than that in the low ALI group (HR: 1.39; 95% CI: 1.03–1.89; p = 0.03).Conclusions: Patients with a low ALI tend to have lower OS among those with metastatic NSCLC, and the ALI can serve as an effective prognostic factor for NSCLC patients.

show abstract

The Efficacy of Different Inflammatory Markers for the Prognosis of Patients with Malignant Tumors

Cited by 14 publications

References 61 publications

Blood immune indexes can predict lateral lymph node metastasis of thyroid papillary carcinoma

Blood immune indexes can predict lateral lymph node metastasis of thyroid papillary carcinoma

Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment

A Low Advanced Lung Cancer Inflammation Index Predicts a Poor Prognosis in Patients With Metastatic Non–Small Cell Lung Cancer

Contact Info

Product

Resources

About